Macquarie Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Macquarie Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-509	Closed	-$11K	–	1711
2025 Q1	$11K	Sell	509 -146	-22%	-$3K	﹤0.01%	1640
2024 Q4	$13K	Buy	655 +155	+31%	+$3.54K	﹤0.01%	1577
2024 Q3	$12K	Buy	+500	New	+$12.2K	﹤0.01%	1620
2022 Q4	–	Sell	-4,020	Closed	-$56K	–	1948
2022 Q3	$56K	Sell	4,020 -333	-8%	-$3.79K	﹤0.01%	1924
2022 Q2	$42K	Hold	4,353	–	–	﹤0.01%	2096
2022 Q1	$43K	Hold	4,353	–	–	﹤0.01%	2189
2021 Q4	$51K	Hold	4,353	–	–	﹤0.01%	2158
2021 Q3	$50K	Buy	4,353 +4,020	+1,207%	+$52.4K	﹤0.01%	2237
2021 Q2	$5K	Hold	333	–	–	﹤0.01%	2527
2021 Q1	$6K	Sell	333 -158	-32%	-$3.23K	﹤0.01%	2437
2020 Q4	$9K	Hold	491	–	–	﹤0.01%	2313
2020 Q3	$8K	Hold	491	–	–	﹤0.01%	2301
2020 Q2	$13K	Buy	+491	New	+$10.3K	﹤0.01%	2254

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Macquarie Group's KNSA Position: Q2 2025 in Review

Macquarie Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2025, closing a stake of 509 shares — an estimated $11K sold.

Macquarie Group first reported a position in KNSA in Q2 2020 and held it in 13 quarters. The position peaked at $56K in Q3 2022. 189 funds tracked by Wall St. Rank hold KNSA as of Q2 2025.

Macquarie Group reported no remaining Kiniksa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Macquarie Group sold 509 Kiniksa Pharmaceuticals shares in Q2 2025, an estimated $11K.
Macquarie Group first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 13 quarters.
Macquarie Group's Kiniksa Pharmaceuticals position peaked at $56K in Q3 2022.
189 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2025.

Based on Macquarie Group's 13F filing for Q2 2025, filed 14 Aug 2025.